Compare NBHC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | NVCR |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2011 | 2015 |
| Metric | NBHC | NVCR |
|---|---|---|
| Price | $43.10 | $17.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.67 | $28.08 |
| AVG Volume (30 Days) | 452.2K | ★ 1.7M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 1.04 | N/A |
| Revenue | $47,100,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $39.96 | $7.72 |
| Revenue Next Year | $7.14 | $6.74 |
| P/E Ratio | $41.86 | ★ N/A |
| Revenue Growth | 2.86 | ★ 8.28 |
| 52 Week Low | $35.06 | $9.82 |
| 52 Week High | $47.28 | $21.45 |
| Indicator | NBHC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 55.77 |
| Support Level | $42.95 | $14.84 |
| Resistance Level | $43.98 | $18.48 |
| Average True Range (ATR) | 0.73 | 0.73 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 55.49 | 87.80 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.